Antidrug antibodies to tumour necrosis factor specific neutralising agents in chronic inflammatory diseases: A real issue, a clinical perspective; comment on the article by Vincent et al

Annals of the Rheumatic Diseases

Volumn 72, Issue 7, 2013, Pages

  Den Broeder, Alfons A ^a   Van Der Maas, Aatke ^a   Van Den Bemt, Bart J F ^a  

^a Sint Maartenskliniek ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

CHRONIC INFLAMMATION; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HUMAN; LETTER; PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT ONSET STILL'S DISEASE; AMYLOIDOSIS; ANALGESICS;

ANIMALS; ANTIRHEUMATIC AGENTS; BIOLOGICAL AGENTS; HUMANS; IMMUNE SYSTEM DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878398895     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203648     Document Type: Letter

References (7)

1. Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralizing agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78.
2. Pavelka K, Jarosov K, Such D, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its ef ficacy. Ann Rheum Dis 2009;68:1285-9.
3. van den Bemt BJF, den Broeder AA, Snijders GF, et al. Sustained effect after lowering high dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 2008;67:1697-701.
4. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
5. Aarnoutse RE, Schapiro JM, Boucher CA, et al. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 2003;63:741-53. (Pubitemid 36428444)
6. Krieckaert C, Nair SC, Nurmohamed MT, et al. Evaluating the cost-effectiveness of personalized treatment with adalimumab using serum drug level and anti-adalimumab antibodies in rheumatoid arthritis patients. Ann Rheum Dis 2012;71(suppl 3):104.
7. Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumabx in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.